Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0080877 |
| Name | astrocytoma, IDH-mutant, grade 4 |
| Definition | An IDH-mutant anaplastic astrocytoma that is characterized by the presence of necrosis and/or microvascular proliferation or homozygous deletion of CDKN2A and/or CDKN2B genes. The term glioblastoma no longer applies to central nervous system WHO grade 4 IDH-mutant astrocytomas. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer cell type cancer high grade glioma malignant astrocytoma anaplastic astrocytoma IDH-mutant anaplastic astrocytoma astrocytoma, IDH-mutant, grade 4 |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| IDH1 act mut | Vorasidenib | astrocytoma, IDH-mutant, grade 4 | sensitive | detail... |
| IDH2 act mut | Vorasidenib | astrocytoma, IDH-mutant, grade 4 | sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05303519 | Phase II | DS-1001b | Safusidenib Phase 2 Study in IDH1 Mutant Glioma | Recruiting | USA | 0 |
| NCT05917145 | Phase I | WSD-0628 | ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma | Recruiting | USA | 0 |
| NCT06047379 | Phase Ib/II | NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Recruiting | USA | 0 |
| NCT06161974 | Phase II | Olutasidenib + Temozolomide | Study of Olutasidenib and Temozolomide in HGG | Recruiting | USA | NLD | GBR | DEU | CAN | AUS | 0 |
| NCT06478212 | Phase Ib/II | Temozolomide + Vorasidenib | Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma | Recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | AUT | 2 |
| NCT06630260 | Phase Ib/II | Defactinib + RO5126766 + Temozolomide Defactinib + RO5126766 | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours (5G-RUBY) | Recruiting | GBR | 0 |
| NCT06632236 | Phase I | Amivantamab-vmjw | 5G-EMERALD: Amivantamab in Malignant Brain Tumours (5G-EMERALD) | Recruiting | GBR | 0 |
| NCT06815029 | Phase I | TGFbetaR2KO/IL13Ralpha2 CAR-T cells | Intracranial Genetically Modified Immune Cells (TGFbetaR2KO/IL13Ralpha2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma | Recruiting | USA | 0 |
| NCT06894979 | Phase I | AZD1390 | Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma | Recruiting | USA | 0 |
| NCT06896110 | Phase I | Azacitidine + Nivolumab | Intrathecal Azacitidine and Nivolumab in Patients with Recurrent High-grade Glioma | Enrolling by invitation | USA | 0 |
| NCT06917885 | Phase I | CUE-102 | CUE-102 in Recurrent Glioblastoma | Recruiting | USA | 0 |